Literature DB >> 7125628

In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species.

I Haller.   

Abstract

Metronidazole and its two principal oxidative metabolites were tested in vitro against 20 clinical isolates of the Bacteroides fragilis group. Both metabolites were bactericidal, and the exhibited 65 and 5%, respectively, of the inhibitory effect of metronidazole. Additive or weak synergistic effects resulted in combination with the parent compound.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7125628      PMCID： PMC183695          DOI： 10.1128/AAC.22.1.165

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Bioassay of metronidazole with either anaerobic or aerobic incubation.

Authors:  E D Ralph; W M Kirby
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

2.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

3.  Medium for use in antibiotic susceptibility testing of anaerobic bacteria.

Authors:  T D Wilkins; S Chalgren
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

4.  Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

Authors:  V L Sutter; A L Barry; T D Wilkins; R J Zabransky
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

5.  Use of high-pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration.

Authors:  L A Wheeler; M De Meo; M Halula; L George; P Heseltine
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

6.  Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose.

Authors:  G W Houghton; P S Thorne; J Smith; R Templeton; J Collier
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

7.  Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects.

Authors:  I Nilsson-Ehle; B Ursing; P Nilsson-Ehle
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191
  7 in total
  8 in total

1.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers.

Authors:  M N Muscará; J Pedrazzoli; E L Miranda; J G Ferraz; E Hofstätter; G Leite; A F Magalhães; S Leonardi; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

2.  Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Authors:  Kelly A Sprandel; Christopher A Schriever; Susan L Pendland; John P Quinn; Mark H Gotfried; Suzanne Hackett; Mary Beth Graham; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

5.  In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

Authors:  S L Pendland; S C Piscitelli; P C Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Single dose prophylaxis with metronidazole in infants during abdominal surgery: a pharmacokinetic study.

Authors:  A Rubenson; A Rosetzsky
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations.

Authors:  M J Pavicić; F Namavar; T Verboom; A J van Winkelhoff; J De Graaff
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.

Authors:  Joseph F Standing; Martin O Ongas; Caroline Ogwang; Nancy Kagwanja; Sheila Murunga; Shalton Mwaringa; Rehema Ali; Neema Mturi; Moline Timbwa; Christine Manyasi; Laura Mwalekwa; Victor L Bandika; Bernhards Ogutu; Joseph Waichungo; Karin Kipper; James A Berkley
Journal:  Clin Pharmacol Ther       Date:  2018-04-19       Impact factor: 6.875
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.